Skip to content
Skip to navigation
Skip to footer

Press Releases

View global media contacts

Home / Media Centre / Press Releases

Latest

Two datopotamab deruxtecan applications validated in the EU for patients with advanced nonsquamous non-small cell lung cancer or HR-positive, HER2-negative breast cancer
4 March 2024
Voydeya recommended for approval in the EU by CHMP as add-on treatment to ravulizumab or eculizumab for adults with PNH who have residual haemolytic anaemia
26 February 2024
Acquisition of Gracell completed
22 February 2024
Acquisition of Icosavax Completed
19 February 2024
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
19 February 2024
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
19 February 2024
Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
19 February 2024
Full Year and Q4 2023 results
8 February 2024
Positive high-level results from Japan Phase III trial of acoramidis in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) showed consistency with global ATTRibute-CM Phase III trial
2 February 2024
Enhertu granted Priority Review in the US for patients with metastatic HER2-positive solid tumours
29 January 2024

1
2
3
28
next

Can't find what you are looking for? Our Press Release archive contains all of our press releases dated before 2020 so you should be able to find just what you are looking for.

Explore archive